Information Provided By:
Fly News Breaks for April 21, 2016
SRPT
Apr 21, 2016 | 09:12 EDT
Janney Capital analyst Debjit Chattopadhyay said the just-released briefing documents for the FDA's panel meeting on Sarepta Therapeutics' eteplirsen show the agency is "clearly not backing down" from its initial negative review, adding that the AdComm "seems more like a farce to placate the external pressure groups." The most logical outcome of a Complete Response Letter being issued "seems to be a foregone conclusion," contends Chattopadhyay, who lowered his fair value estimate on Sarepta shares to $15 from $19.
News For SRPT From the Last 2 Days
There are no results for your query SRPT